Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01MH084757 | U.S. NIH Grant/Contract | View source | |
| 1R01MH084757-01A1 | U.S. NIH Grant/Contract | View source | |
| DAHBR 9A-ASGA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will test a therapy for both helping people adhere to their HIV medication regimens and treating them for depression.
People infected with HIV are more likely to suffer from depression than those not infected, with studies finding anywhere from 20% to 50% of HIV-infected individuals having significant depressive symptoms. Depression, in addition to causing persistent sadness and inability to feel pleasure, is related to a lack of HIV treatment adherence. Treatment adherence (making sure to take every pill as prescribed by doctors) is critically important to successful treatment of HIV, because missing even a few doses gives the HIV virus an opportunity to develop immunity to the medication. Poor adherence is related to worse medical outcomes, but even a small, 10% improvement rate in adherence may improve these outcomes. This study will test the efficacy of cognitive behavioral therapy (CBT) that addresses both depression and treatment adherence for HIV-infected people.
Participation in this study will last 1 year, including follow-up visits. All participants will complete an initial one-visit intervention addressing treatment adherence. Then after 2 weeks, participants will be randomly assigned to one of three conditions: CBT for HIV medication adherence and depression (CBT-AD), information and supportive psychotherapy for HIV medication adherence and depression (ISP-AD), or enhanced treatment as usual (ETAU). Participants receiving CBT-AD and ISP-AD will complete 12 therapy sessions over 4 months and will be asked to report any changes to their psychological or HIV treatments. CBT-AD will involve learning to identify and change problematic patterns of thought and behavior, while ISP-AD will involve education and supportive psychotherapy. Participants receiving ETAU will receive only the initial session on HIV medication adherence and will be asked about their psychological and HIV treatment every other week for 4 months.
Major study assessments will take place at baseline and after 4, 8, and 12 months. Assessments will include completing diagnostic interviews and questionnaires, measuring medication adherence through an electronic pill cap, and determining CD4 cell count and viral load (indicators of HIV treatment effectiveness).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enhanced treatment as usual | Active Comparator | Participants will receive the life-steps intervention and treatment as usual. |
|
| CBT for adherence and depression (CBT-AD) | Experimental | Participants will receive the life-steps and CBT-AD interventions. |
|
| ISP for adherence and depression (ISP-AD) | Active Comparator | Participants will receive the life-steps and ISP-AD interventions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD) | Behavioral | 12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications |
| Measure | Description | Time Frame |
|---|---|---|
| changes in HIV medication adherence, as measured by electronic medication event monitoring system (MEMS) pill-cap scores | HIV medication adherence is assessed more frequently during the acute study period (baseline to post-treatment), and then at the follow up major visits. | Measured at each visit - baseline, interim visits, and after 4, 8, and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| changes in Severity of depression, as assessed on the Montgomery-Asberg Depression Rating Scale (MADRS) by a blinded independent assessor | Measured at baseline and after 4, 8, and 12 months | |
| changes in depression, as measured by the blinded assessor CGI rating |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven A. Safren, PhD | Partners HealthCare | Principal Investigator |
| C. Andres Bedoya, PhD | Partners HealthCare | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | ||
| Fenway Community Health Center |
Not provided
Not provided
Not provided
Not provided
Not provided
| Life-steps adherence treatment | Behavioral | Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management |
|
| Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD) | Behavioral | 12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications. |
|
| Measured at baseline and after 4, 8, and 12 months |
| changes in RNA viral load | Measured at baseline and after 4, 8, and 12 months |
| changes in CD4 cell count | Measured at baseline and after 4, 8, and 12 months |
| changes in self-reported depression (CESD) | This is measured more frequently during the acute phase (pretreatment to post-treatment) then at the follow up assessments. | Measured at each visit |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| Butler Hospital | Providence | Rhode Island | 02906 | United States |
| The Miriam Hospital | Providence | Rhode Island | 02906 | United States |
| ID | Term |
|---|---|
| D003863 | Depression |
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015928 | Cognitive Behavioral Therapy |
| ID | Term |
|---|---|
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided